Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Donal M. Kelly"'
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL/Apo-2L) has emerged as a promising anticancer agent. However, resistance to TRAIL is likely to be a major problem, and sensitization of cancer cells to TRAIL may therefore be an importa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45bce1d67630d66ee32bc58381f1e107
https://doi.org/10.1158/0008-5472.c.6497430
https://doi.org/10.1158/0008-5472.c.6497430
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 3 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771a4e22b5494372c8e40f256dd2410f
https://doi.org/10.1158/0008-5472.22374408
https://doi.org/10.1158/0008-5472.22374408
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 4 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897cc08494e7ed1138d518d5c847436b
https://doi.org/10.1158/0008-5472.22374405
https://doi.org/10.1158/0008-5472.22374405
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 1 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e91db485c26dda29269f8dfa9d487
https://doi.org/10.1158/0008-5472.22374414
https://doi.org/10.1158/0008-5472.22374414
Autor:
Daniel B. Longley, Patrick G. Johnston, Dean A. Fennell, Susan Stokesberry, Joan Kyula, Donal M. Kelly, Sandra Van Schaeybroeck
Supplementary Figure 2 from Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d6a724a528b1ec317d1b6ac8d4e6a2
https://doi.org/10.1158/0008-5472.22374411.v1
https://doi.org/10.1158/0008-5472.22374411.v1
Autor:
Daniel B. Longley, Patrick G. Johnston, Joan Kyula, Donal M. Kelly, Dean A. Fennell, Sandra Van Schaeybroeck, Susan Stokesberry
Publikováno v:
Cancer Research. 68:8312-8321
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL/Apo-2L) has emerged as a promising anticancer agent. However, resistance to TRAIL is likely to be a major problem, and sensitization of cancer cells to TRAIL may therefore be an importa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1f1e354dd2ca57a18f7db4da56df62
https://doi.org/10.1158/0008-5472.can-07-6736
https://doi.org/10.1158/0008-5472.can-07-6736
Autor:
Eric Van Cutsem, Donal M. Kelly, Sandra Van Schaeybroeck, Joan Kyula, Anthi Karaiskou-McCaul, Daniel B. Longley, Patrick G. Johnston, Susan Stokesberry
Publikováno v:
Molecular Cancer Therapeutics. 5:1154-1165
Activating epidermal growth factor receptor (EGFR) mutations have been linked with sensitivity to gefitinib and erlotinib; however, there are no established predictive markers for response to the combination of EGFR inhibitors with standard chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f953d64789ccdb51ac62eeb37fdc5b8
https://doi.org/10.1158/1535-7163.mct-05-0446
https://doi.org/10.1158/1535-7163.mct-05-0446
Autor:
Anthi Karaiskou-McCaul, Eric Van Cutsem, Daniel B. Longley, Patrick G. Johnston, Leeona Galligan, Donal M. Kelly, Sandra Van Schaeybroeck
Publikováno v:
Clinical Cancer Research. 11:7480-7489
Purpose: Up to now, there have been no established predictive markers for response to epidermal growth factor receptor (EGFR/HER1/erbB1) inhibitors alone and in combination with chemotherapy in colorectal cancer. To identify markers that predict resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3579eb14a90e187278c9202543f4ac
https://doi.org/10.1158/1078-0432.ccr-05-0328
https://doi.org/10.1158/1078-0432.ccr-05-0328
Autor:
D. Longley, Susan Stokesberry, Wendy L. Allen, S. Van Schaeybroeck, P.G. Johnston, Donal M. Kelly, Joan Kyula, E. Van Cutsem
Publikováno v:
European Journal of Cancer Supplements. 4:117
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::329bb3e60c2cd17f8189ff3bf68d701b
https://doi.org/10.1016/s1359-6349(06)70384-6
https://doi.org/10.1016/s1359-6349(06)70384-6